Pharma sector stocks fall today, July 23: Panacea Biotec drops 3.21%, Dr. Reddys Lab declines 2.87%, Ajanta Pharma down 2.27%
NiveshIQ
NSE: AJANTPHARM · Pharma
Ajanta Pharmaceuticals Ltd.
₹3,396.50▲ ₹54.10 (+1.62%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AJANTPHARM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Ajanta Pharmaceuticals Ltd.
Ajanta Pharma Limited is a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers a range of products, including chronic and acute therapies, branded generic products, and various dosage forms. Its product portfolio covers therapeutic areas such as cardiology, dermatology, ophthalmology, and pain management. Ajanta Pharma operates in key markets including India, Africa, Asia, the United States, and internationally. The company has a strong presence in the Indian market and is expanding its global footprint. With a revenue of ₹5453 Cr and net income of ₹1056 Cr, Ajanta Pharma has a solid financial foundation. The company has a buy rating from analysts with a target price of ₹3303, indicating potential for fut
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹4,208 Cr +12.40% | ₹4,648 Cr +10.50% | ₹5,454 Cr +17.30% |
| EBITDA Margin | 27.42% | 27.09% | 26.69% |
| Net Profit | ₹816.00 Cr +38.80% | ₹920.00 Cr +12.70% | ₹1,056 Cr +14.70% |
| EPS | ₹63.69 | ₹73.68 | ₹84.53 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Pharma sector stocks fall today, July 23: Panacea Biotec drops 3.21%, Dr. Reddys Lab declines 2.87%, Ajanta Pharma down 2.27%
Ajanta Pharma to host Q1 FY27 earnings call on July 30
🔒
+ 3 more stories about Ajanta Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹1, 422 Cr, PAT ₹267 Cr, EPS ₹21.35, EBITDA margin 27.8%. Growth context: revenue YoY +21.5%, PAT YoY +18.5%, revenue QoQ +3.4%, PAT QoQ -2.7%. Street verdict: beat, revenue surprise +7.1%, PAT surprise +5.0%.
Management commentary highlights order wins, deal pipeline, and backlog build as key near-term growth drivers, which are...
FY26 (last completed FY): revenue ₹5, 454 Cr, PAT ₹1, 056 Cr, EBITDA margin 26.7%, EPS ₹84.53. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AJANTPHARM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AJANTPHARM alongside your other holdings
Unlock full AJANTPHARM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Ajanta Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Ajanta Pharmaceuticals Ltd. (AJANTPHARM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Ajanta Pharmaceuticals Ltd.?
Ajanta Pharmaceuticals Ltd. operates in the Pharma sector with a market capitalisation of ₹3,791,796.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.